These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24210911)

  • 1. Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?
    Azad AA; Eigl BJ
    Eur Urol; 2014 Feb; 65(2):504-5. PubMed ID: 24210911
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
    Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of abiraterone acetate withdrawal.
    Witjes JA
    Eur Urol; 2013 Sep; 64(3):517-8. PubMed ID: 23806520
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
    Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
    Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?
    Maines F; Veccia A; Caffo O
    Eur Urol; 2014 Jul; 66(1):179-80. PubMed ID: 24685435
    [No Abstract]   [Full Text] [Related]  

  • 6. Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate.
    Hung SC; Wang SS; Li JR; Chen MC; Yang CK; Chen CS; Ho HC; Chiu KY; Cheng CL; Chang CH; Ou YC
    Anticancer Res; 2018 Sep; 38(9):5429-5436. PubMed ID: 30194199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?
    Caffo O; Palermo A; Veccia A; Maines F; Chierichetti F; Galligioni E
    Clin Genitourin Cancer; 2013 Dec; 11(4):e10-4. PubMed ID: 23810439
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictive factors for abiraterone withdrawal syndrome.
    Almendros S; Berenguer-Francés MA; Ferrer-González F; Boladeras A; Guix I; Guedea F
    Actas Urol Esp (Engl Ed); 2019; 43(6):300-304. PubMed ID: 31060755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there an antiandrogen withdrawal syndrome with enzalutamide?
    Rodriguez-Vida A; Bianchini D; Van Hemelrijck M; Hughes S; Malik Z; Powles T; Bahl A; Rudman S; Payne H; de Bono J; Chowdhury S
    BJU Int; 2015 Mar; 115(3):373-80. PubMed ID: 24906049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
    Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Terada N; Maughan BL; Akamatsu S; Kobayashi T; Yamasaki T; Inoue T; Kamba T; Ogawa O; Antonarakis ES
    Int J Urol; 2017 Jun; 24(6):441-448. PubMed ID: 28455853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
    Kim KB; Jo JK; Ahn S; Lee S; Jeong SJ; Hong SK; Byun SS; Lee SE
    Korean J Urol; 2015 Aug; 56(8):580-6. PubMed ID: 26279827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
    Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
    Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.
    Di Lorenzo G; Sonpavde G; Pond G; Lucarelli G; Rossetti S; Facchini G; Scagliarini S; Cartenì G; Federico P; Daniele B; Morelli F; Bellelli T; Ferro M; De Placido S; Buonerba C
    Eur Urol Focus; 2018 Dec; 4(6):874-879. PubMed ID: 28753882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
    Zhou ZR; Liu SX; Zhang TS; Xia J; Li B
    Asian Pac J Cancer Prev; 2014; 15(3):1313-20. PubMed ID: 24606458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.
    McKay RR; Werner L; Fiorillo M; Roberts J; Heath EI; Bubley GJ; Montgomery RB; Taplin ME
    Clin Genitourin Cancer; 2017 Aug; 15(4):463-471. PubMed ID: 27890446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid oral desensitization protocol to abiraterone acetate.
    Verdu M; Torres-Degayon V; Hassan-Bennis M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):668-669. PubMed ID: 29432966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.